Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

ONCOLOGY R&D GERMANY

Signature(s)

Amount
€ 450,000,000
Countries
Sector(s)
Germany : € 450,000,000
Industry : € 450,000,000
Signature date(s)
18/11/2008 : € 450,000,000
Link to source
Data sheet
ONCOLOGY R&D GERMANY
Other links
Summary sheet
Oncology R&D Germany

Summary sheet

Release date
9 June 2008
Status
Reference
Signed | 18/11/2008
20070422
Project name
Promoter - financial intermediary
Oncology R&D Germany
A leading pharmaceutical company carrying out internationally reputable research and development activities.
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 450 million.
EUR 1000 million.
Location
Sector(s)
Description
Objectives

The project comprises the financing of expenditure under the Research and Development programmes of a major European pharmaceutical company for the development of new medical treatments in the period 2008-2011.

The project supports the development of new medical treatments.

Environmental aspects
Procurement

R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centers, etc. An EIA therefore is not required by EU Directive 97/11. To be further assessed during appraisal. Compliance of R&D activities with relevant EU legislation will also be verified during appraisal.

The promoter is a private company not operating in the Utilities sector and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.

Link to source
Summary sheet
Oncology R&D Germany
Other links
Data sheet
ONCOLOGY R&D GERMANY

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications